CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus

CONCLUSIONS: Data from the combined cohort suggest that rilematovir has a small but favorable antiviral effect of indeterminate clinical relevance compared with placebo, as well as a favorable safety profile. Safe and effective therapeutic options for RSV in infants and young children remain an unmet need.CLINICAL TRIAL REGISTRATION: EudraCT Number: 2016-003642-93; ClinicalTrials.gov Identifier: NCT03656510. First posted date: 4 September, 2018.PMID:38649595 | DOI:10.1007/s40272-024-00625-x

Source: Paediatric Drugs - April 22, 2024 Category: Pediatrics Authors: Fernando Ferrero Chien-Yu Lin Johannes Liese Kleber Luz Tatyana Stoeva Agnes Nemeth Manuel Gij ón Cristina Calvo Silvina Natalini Teck-Hock Toh Sofie Deleu Bohang Chen Sarah Rusch Beatriz L ópez Sánchez Illse Leipoldt Leen Vijgen Dymphy Huntjens Trista Source Type: research